OGT has launched the SureSeq™ myPanel Myeloid Fusion MRD Panel, which it describes as the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML). The Oxford, UK-based company announced in October 2026 that the panel is now publicly available for customers to purchase and implement in their own workflows.

Detecting fusions at MRD-level sensitivity

OGT said that genomic AML workflows traditionally cover only part of the genomic picture, with important fusion events at risk of going undetected. The new panel is a custom SureSeq NGS panel developed in collaboration with Roswell Park Comprehensive Cancer Center, using OGT’s myPanel custom service. It enables the detection of AML-associated fusion events and identifies MECOM expression levels at MRD-level sensitivity, generating broader fusion insights for AML sample cohorts in a single assay. The RNA-based panel is designed to detect, analyse and track high-impact fusion events across multiple timepoints.

“Important fusion signals are difficult to identify when workflows depend on multiple assays or have insufficient sensitivity,” said Adrian Smith, chief executive officer at OGT. “We’re proud to launch the first dedicated Fusion MRD NGS panel for AML that empowers laboratories with a focused tool to detect, analyse and track fusion events at MRD-level sensitivity. Used independently or alongside our SureSeq Myeloid MRD Plus NGS Panel, this panel has the potential to capture a wide range of disease-associated fusion events at MRD-levels of sensitivity that may otherwise be missed, and thus provides a broader genomic profile of AML samples for deeper insights.”

Initial study at Roswell Park

In an initial study of clinical research samples carried out at Roswell Park Comprehensive Cancer Center, the SureSeq myPanel Fusion MRD NGS workflow detected key disease-associated fusion events, including BCR::ABL1 and PML::RARA, in serial dilutions as low as 1% tumour cells.

“The addition of RNA fusion detection represents an important opportunity to broaden the reach of molecular MRD assessment to the approximately 20–25% of AML cases associated with fusion-driven disease,” said Dr Sean Glenn, director of the Advanced Molecular Diagnostics Laboratory, Roswell Park Comprehensive Cancer Center. “By providing molecular markers of residual leukaemia that can be monitored over time, fusion transcripts can support residual disease assessment, including in samples that lack an informative DNA mutation.”

Analysis software and combined use

The panel forms part of the end-to-end SureSeq NGS workflow. OGT’s complimentary NGS analysis software, Interpret, allows laboratories to analyse, track and visualise variants, including fusion events, across multiple timepoints within a single software environment. It is available through cloud and local installation options, with options for integrating third-party tools including QIAGEN Clinical Insight (QCI®) Interpret, so that clinical researchers can follow AML disease dynamics and generate genomic insights from their NGS data.

The panel can be used as a standalone assay for fusion event detection, or along-side the SureSeq Myeloid MRD Plus NGS Panel for broader MRD characterisation. Together, the two panels support MRD-level detection of SNVs, indels, ITDs and fusion events in AML samples, allowing researchers to expand the range of detectable variants without relying on multiple single-analyte assays. SureSeq products are for research use only and not for use in diagnostic procedures.

For more information, visit: https://shorturl.at/VzG0r

Digital issue: Please click here for more information